Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation
This is a non-randomised, open label study for people with advanced cancers that have specific KRAS mutations. Enrolment into the dose exploration cohorts can be from any eligible solid tumour type. Dose excalation will begin at a planned dose level of 180 mg.